Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the ...

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration ...

Novartis NOVN-1.91%decrease; red down pointing triangle said it is launching a direct-to-patient platform in the U.S. to sell a discounted version of its Cosentyx drug, the latest big pharma company ...

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...